186 related articles for article (PubMed ID: 35155191)
1. Identifying the Candidates Who Will Benefit From Extended Pelvic Lymph Node Dissection at Radical Prostatectomy Among Patients With Prostate Cancer.
Yang G; Xie J; Guo Y; Yuan J; Wang R; Guo C; Peng B; Yao X; Yang B
Front Oncol; 2021; 11():790183. PubMed ID: 35155191
[TBL] [Abstract][Full Text] [Related]
2. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
3. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database.
Chen J; Wang Z; Zhao J; Zhu S; Sun G; Liu J; Zhang H; Zhang X; Shen P; Shi M; Zeng H
Sci Rep; 2019 Nov; 9(1):17985. PubMed ID: 31784574
[TBL] [Abstract][Full Text] [Related]
4. Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
Izol V; Ok F; Aslan G; Akdogan B; Sozen S; Ozden E; Celik O; Muezzinoglu T; Turkeri L; Akdogan N; Baltaci S
Prostate; 2022 May; 82(7):763-771. PubMed ID: 35188993
[TBL] [Abstract][Full Text] [Related]
5. The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer.
Doan P; Katelaris A; Scheltema MJ; Hayen A; Amin A; Siriwardana A; Tran M; Geboers B; Gondoputro W; Haynes AM; Matthews J; Delprado W; Stricker PD; Thompson J
BMC Urol; 2023 Apr; 23(1):68. PubMed ID: 37118731
[TBL] [Abstract][Full Text] [Related]
6. Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection.
Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Montorsi F; Saad F; Briganti A; Steuber T; Budäus L; Huland H; Graefen M; Tilki D; Karakiewicz PI
Urol Oncol; 2018 Aug; 36(8):365.e1-365.e7. PubMed ID: 29887241
[TBL] [Abstract][Full Text] [Related]
7. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification.
Leyh-Bannurah SR; Budäus L; Zaffuto E; Pompe RS; Bandini M; Briganti A; Montorsi F; Schiffmann J; Shariat SF; Fisch M; Chun F; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2018 Feb; 36(2):81.e17-81.e24. PubMed ID: 29248430
[TBL] [Abstract][Full Text] [Related]
8. Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.
Gandaglia G; Zaffuto E; Fossati N; Bandini M; Suardi N; Mazzone E; Dell'Oglio P; Stabile A; Freschi M; Montorsi F; Briganti A
BJU Int; 2018 Mar; 121(3):421-427. PubMed ID: 29063734
[TBL] [Abstract][Full Text] [Related]
9. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.
Gandaglia G; Martini A; Ploussard G; Fossati N; Stabile A; De Visschere P; Borgmann H; Heidegger I; Steinkohl F; Kretschmer A; Marra G; Mathieu R; Surcel C; Tilki D; Tsaur I; Valerio M; Van den Bergh R; Ost P; Gontero P; Montorsi F; Briganti A;
Eur Urol; 2020 Aug; 78(2):138-142. PubMed ID: 32268944
[TBL] [Abstract][Full Text] [Related]
10. Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer.
Moschini M; Afferi L; Gandaglia G; D'Andrea D; Zamboni S; Di Bona C; Mordasini L; Mattei A; Baumeister P; Martini A; Burgio G; Shariat SF; Sanchez-Salas R; Cathelineau X; Stabile A; Zaffuto E; Salonia A; Colombo R; Necchi A; Montorsi F; Briganti A; Gallina A
Eur Urol Focus; 2021 Sep; 7(5):1067-1074. PubMed ID: 33020030
[TBL] [Abstract][Full Text] [Related]
11. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
12. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Fossati N; Stabile A; Beauval JB; Malavaud B; Roumiguié M; Robesti D; Dell'Oglio P; Moschini M; Zamboni S; Rakauskas A; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
Eur Urol; 2019 Mar; 75(3):506-514. PubMed ID: 30342844
[TBL] [Abstract][Full Text] [Related]
13. Development and internal validation of a novel nomogram for predicting lymph node invasion for prostate cancer patients undergoing extended pelvic lymph node dissection.
Li Z; Huang Y; Zhao D; Luo X; Wu Z; Zheng X; Xie Y; Liu Y; Wu J; Peng Y; Li Y; Zhou F
Front Oncol; 2023; 13():1186319. PubMed ID: 37223684
[TBL] [Abstract][Full Text] [Related]
14. Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold.
Venclovas Z; Muilwijk T; Matjosaitis AJ; Jievaltas M; Joniau S; Milonas D
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801231
[No Abstract] [Full Text] [Related]
15. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
[TBL] [Abstract][Full Text] [Related]
16. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis.
Chen J; Ni Y; Sun G; Zhu S; Zhao J; Wang Z; Zhang H; Zhu X; Zhang X; Dai J; Shen P; Zeng H
Front Oncol; 2020; 10():607576. PubMed ID: 33324569
[TBL] [Abstract][Full Text] [Related]
18. North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer.
Leyh-Bannurah SR; Budäus L; Pompe R; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Huland H; Graefen M; Karakiewicz PI
Prostate; 2017 Apr; 77(5):542-548. PubMed ID: 28093788
[TBL] [Abstract][Full Text] [Related]
19. Optimal Cut-Off Values of the Positive Lymph Node Ratio and the Number of Removed Nodes for Patients Receiving Resection of Bronchopulmonary Carcinoids: A Propensity Score-Weighted Analysis of the SEER Database.
Chen Q; Li M; Wang P; Chen J; Zhao H; Zhao J
Front Oncol; 2021; 11():696732. PubMed ID: 34367980
[TBL] [Abstract][Full Text] [Related]
20. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.
Suardi N; Larcher A; Haese A; Ficarra V; Govorov A; Buffi NM; Walz J; Rocco B; Borghesi M; Steuber T; Pini G; Briganti A; Mottrie AM; Guazzoni G; Montorsi F; Pushkar D; Van Der Poel H;
Eur Urol; 2014 Oct; 66(4):635-43. PubMed ID: 24411992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
